title: Natural history of the TT virus infection through follow-up of TTV DNA-positive multiple-transfused patients.
abstract: Little is known about the natural history and the pathogenicity of the TT virus (TTV). We present our findings of a cross-sectional study based on the TTV DNA screening of 173 multiple-transfused patients and a longitudinal study based on the follow-up of TTV DNA-positive patients. Overall, 48 patients (27.7%) tested positive for TTV DNA. The influence of the number of blood donor exposures on the prevalence of blood-borne viral infection indicates that TTV, hepatitis C virus (HCV), and an RNA virus known as GB virus C/hepatitis G virus (GBV-C/HGV) share a parenteral transmission, but that TTV, in contrast to the 2 other viruses, is also transmitted by at least another efficient means. The patients having a well-defined date of TTV infection were positive for TTV DNA during a mean period of 3.1 years. A chronic infection was observed in 31 cases (86%). TTV carriage appeared clinically benign in all patients. No clinical evidence of a disease potentially linked to the TTV infection was observed in patients with TTV DNA carriage over several years. The majority of TTV carriers had no biochemical evidence of liver disease. The prevalence of elevated serum alanine aminotransferase (ALT) level was higher in the TTV DNA-positive group, even in the absence of HCV infection, but the observed peaks of ALT level were most often transient and very mild. The prevalence of TTV DNA observed in blood recipients is consistent with that of TTV infection observed in blood donors. TTV infection frequently tends to persist. (Blood. 2000;95:347-351)
authors.affiliation: Institut National de la Transfusion Sanguine, and Faculté Saint-Antoine, Université Pierre et Marie Curie 75012 Paris, France. lefrere@worldnet.fr
authors.forename: J J
authors.initials: JJ
authors.lastname: Lefrère
authors.forename: F
authors.initials: F
authors.lastname: Roudot-Thoraval
authors.forename: F
authors.initials: F
authors.lastname: Lefrère
authors.forename: A
authors.initials: A
authors.lastname: Kanfer
authors.forename: M
authors.initials: M
authors.lastname: Mariotti
authors.forename: J
authors.initials: J
authors.lastname: Lerable
authors.forename: M
authors.initials: M
authors.lastname: Thauvin
authors.forename: G
authors.initials: G
authors.lastname: Lefèvre
authors.forename: P
authors.initials: P
authors.lastname: Rouger
authors.forename: R
authors.initials: R
authors.lastname: Girot
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase / Q000097:blood; D000741:Anemia, Aplastic / Q000097:blood; D000755:Anemia, Sickle Cell / Q000628:therapy; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D004266:DNA Virus Infections / Q000503:physiopathology* / Q000635:transmission*; D004267:DNA Viruses / Q000302:isolation & purification*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D065227:Transfusion Reaction; D017086:beta-Thalassemia / Q000628:therapy
chemical_list: D004279:DNA, Viral; D000410:Alanine Transaminase